Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection

American Journal of Transplantation

Volumn 3, Issue 11, 2003, Pages 1355-1362

  Ehst, Benjamin D ^a   Ingulli, Elizabeth ^a   Jenkins, Marc K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adoptive transfer; Ovalbumin; Skin

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; LIGAND; MINOR HISTOCOMPATIBILITY ANTIGEN; OVALBUMIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CELL STIMULATION; CHICKEN; CONTROLLED STUDY; GRAFT REJECTION; HISTOCOMPATIBILITY; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; SKIN GRAFT; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD45; ANTIGENS, THY-1; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL MEMBRANE; CHICKENS; GRAFT SURVIVAL; LIGANDS; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; OVALBUMIN; PLASMIDS; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TIME FACTORS; TRANSGENES;

EID: 0142122407     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00246.x     Document Type: Article

References (45)

1. Arakelov A, Lakkis FG. The alloimmune response and effector mechanisms of allograft rejection. Semin, Nephrol 2000; 20: 95-102.
2. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med 1986; 163: 998-1011.
3. Valujskikh A, Matesic D, Heeger PS. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen. Transplantation 1999; 68: 1029-1036.
4. Roopenian D. What are minor histocompatibility loci? A new look at an old question. Immunol Today 1992; 13: 7-10.
5. Rosenberg A, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992; 10: 333-358.
6. Rees MA, Rosenberg AS, Munitz TI, Singer A. In vivo induction of antigen-specific transplantation tolerance to Qal a by exposure to alloantigen in the absence of T-cell help. Proc Natl Acad Sci U S A 1990; 87: 2765-2769.
7. Wettstein PJ, Korngold R. T cell subsets required for in vivo and in vitro responses to single and multiple minor histocompatibility antigens. Transplantation 1992; 54s: 296-307.
8. Roopenian DC, Davis AP, Christianson GJ, Mobraaten LE. The functional basis of minor histocompatibility loci. J Immunol 1993; 151: 4595-4605.
9. Antoniou A, McCormick D, Scott D et al. T cell tolerance and activation to a transgene-encoded tumor antigen. Eur J Immunol 1996; 26: 1094-1102.
10. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996; 184: 863-871.
11. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68: 8056-8063.
12. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693-702.
13. Simpson E, Scott D, James E et al. Minor H antigens: genes and peptides. Transpl Immunol 2002; 10: 115-123.
14. Ehl S, Aichele P, Ramseier H et al. Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat Med 1998; 4: 1015-1019.
15. Gilot BJ, Hara M, Jones ND et al. Visualization of the in vivo generation of donor antigen-specific effector CD8+ T cells during mouse cardiac allograft rejection: in vivo effector CD8+ T cell generation during allograft rejection. Transplantation 2000; 69: 639-648.
16. Delfs MW, Furukawa Y, Mitchell RN, Lichtman AH. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection. Transplantation 2001; 71: 606-610.
17. Choi EY, Yoshimura Y, Christianson GJ et al. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J Immunol 2001; 166: 4370-4379.
18. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27.
19. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76: 34-40.
20. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-785.
21. b gene: evidence for gene conversion as a mechanism for the generation of polymorphism in histocompatibility antigens. EMBO J 1983; 2: 453-462.
22. b molecule using a retroviral shuttle vector. Immunogenetics 1991; 34: 62-65.
23. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
24. Reinhardt RL, Khoruts A. Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001; 410: 101-105.
25. Ambrose HW, Ambrose KP. A Handbook of Biological Investigation, 4th edn. Winston, Salem: Hunter Textbooks Inc., 1987
26. b-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur J Immunol 1992; 22: 2663-2667.
27. McReynolds L, O'Malley BW, Nisbet AD et al. Sequence of chicken ovalbumin mRNA. Nature 1978; 273: 723-728.
28. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6: 715-726.
29. Bevan MJ. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J Exp Med 1975; 142: 1349-1364.
30. Gordon RD, Simpson E, Samelson LE. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. J Exp Med 1975; 142: 1108-1120.
31. McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science 1995; 268: 106-111.
32. Busch DH, Pilip IM, Vijh S, Pamer EG. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 1998; 8: 353-362.
33. Murali-Krishna K, Altman JD, Suresh M et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187.
34. Graff RJ, Hildemann WH, Snell GD. Histocompatibility genes of mice. VI. Allografts in mice congenic at various non-H-2 histocompatibility loci. Transplantation 1966; 4: 425-437.
35. Wettstein PJ, Jewett L, Faas S, Brinster RL, Knowles BB. SV40 T-antigen is a histocompatibility antigen of SV40-transgenic mice. Immunogenetics 1988; 27: 436-441.
36. Dumois JA, VanderVegt FP, Kopp JB, Marinos NJ, Rooney JF, Notkins AL. Transplantation of skin from human immunodeficiency virus type 1-transgenic mice to normal congenic mice results in graft rejection. J Infect Dis 1995; 172: 232-234.
37. Klinge H, Roopenian DC. The same genetic regions encode minor histocompatibility antigens detected in the context of different MHC haplotypes. Transplantation 1999; 67: 1178-1183.
38. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 2000; 191: 541-550.
39. Marzo AL, Kinnear BF, Lake RA et al. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
40. Kurts C, Carbone FR, Barnden M et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997; 186: 2057-2062.
41. Kedl RM, Mescher MF. Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor. J Immunol 1997; 159: 650-663.
42. Shrikant P, Mescher MF. Control of syngeneic turnor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 1999; 162: 2858-2866.
43. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
44. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
45. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.